As the capstone in a multi-year transformation process, on May 9th, our parent company unveiled its new name and brand – Revvity. For more than five years, EUROIMMUN has been part of PerkinElmer, Inc., which completed a divestiture of its…
Read more
The cytoskeleton protein septin-3 has been identified as a novel target antigen of autoantibodies in patients with paraneoplastic cerebellar ataxia. The new biomarker was discovered in a collaborative study between scientists at EUROIMMUN, the University of Heidelberg and further clinics…
Read more
Deep neural networks incorporating segmentation provide highly accurate classification of immunofluorescence patterns on the tissue substrates esophagus and sal…
Microscopy is a fundamental tool in biomedical research and clinical diagnostics. However, each laboratory has different requirements for its instruments: While…
EUROIMMUN ELISAs based on recombinant antigens p52 (IgM) and glycoprotein B (IgG) from cytomegalovirus (CMV) provided a higher rate of conclusive results in fir…
EUROIMMUN ELISAs for detection of antibodies against Crimean-Congo haemorrhagic fever virus (CCHFV) reliably identify acute CCHF cases and are suitable for labo…